Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy

Citations Over TimeTop 10% of 2008 papers

Abstract

Endoglin (CD105) is an accessory protein of the transforming growth factor-beta receptor system expressed on vascular endothelial cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively in the context of this disease. The expression of endoglin is elevated on the endothelial cells of healing wounds, developing embryos, inflammatory tissues, and solid tumors. Endoglin is a marker of activated endothelium, and its vascular expression is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases. Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results.

Related Papers

• → Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia(2017)101 cited
• → Angiogenesis regulation by TGFβ signalling: clues from an inherited vascular disease(2011)52 cited
• → Research on potential biomarkers in hereditary hemorrhagic telangiectasia(2015)41 cited
• → Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT)(2010)31 cited
• → Involvement of the TGF-β superfamily signalling pathway in hereditary haemorrhagic telangiectasia(2010)18 cited